![]()
|
|
||||||||
J. Biol. Chem., Vol. 275, Issue 22, 16459-16465, June 2, 2000
From the Department of Biological Chemistry, The Weizmann Institute of Science, Rehovot 76100, Israel
Received for publication, December 6, 1999, and in revised form, February 10, 2000
| |
ABSTRACT |
|---|
|
|
|---|
TAFII105 is a TFIID-associated
factor highly expressed in B lymphocytes. This subunit is found in a
small portion of TFIID complexes and is homologous to human
TAFII130 and Drosophila TAFII110. In the present study we show that TAFII105 is involved in
transcription activation directed by the B cell-specific octamer
element found in many B cell-specific genes. B cells overexpressing
TAFII105 display higher octamer-dependent
transcription, whereas expression of a C-terminal truncated form of
TAFII105 inhibits octamer transcription in a dominant
negative manner. In addition, antibodies directed against
TAFII105 specifically inhibit octamer-dependent
transcription. Reporter gene analysis revealed that
TAFII105 elevates octamer transcription in the presence of
OCA-B, a cofactor subunit of Oct1 and Oct2 proteins. In
vitro binding assays and functional studies established that the
effect of TAFII105 on octamer activity involves interaction
of TAFII105 with octamer-binding complexes via the
C-terminal activation domain of OCA-B. These findings link
TAFII105 coactivator function to B cell-specific transcription.
The program of B cell-specific gene expression during development
is highly controlled and is governed by gene-specific organization of
DNA regulatory elements and combinatorial interactions of ubiquitous and cell type-specific transcription factors and cofactors. In recent
years significant progress has been made in identifying and
understanding the physiological role of transcription factors involved
in B cell development (1). However, much less is known about the
mechanism underlying the transcription activation process by these
factors. Considering the accumulating evidence indicating that
interactions of activators with various components of the general
transcription apparatus are essential for transcription activation
process, it is reasonable that similar mechanisms apply also for B cell
transcription factors.
Several studies implicated the basal transcription factor TFIID as
potential target for specific activation domains of activators (2, 3).
TFIID is a multiprotein complex consisting of TATA-binding protein
(TBP) and associated factors,
TAFs1 (4-8). TFIID is
required for directing core promoter recognition and pre-initiation
complex assembly (9, 10). In vitro transcription studies
have indicated that the TAF subunits play a crucial role as activation
domain mediators (coactivators) through direct interaction with
activators (11-13). In addition, certain TAFs also function as
promoter selectivity factors (14, 15). Several reports suggested that
certain TAFs play an important role in gene-specific transcriptional
activation in vivo in high eukaryotes (16-20). Recent
genetic experiments in yeast with individual TAF mutants suggested
that, whereas some TAFs are essential for transcription of the majority
of class II genes (21-26), certain TAFs are not generally required for
transcription activation (27-29). Due to a lack of additional genetic
studies in metazoans, little is known about the transcription
regulatory pathways that specifically require the activities of the TAFs.
Previously we have cloned a subunit of TFIID, TAFII105,
that is related to the coactivator subunit hTAFII130 and to
Drosophila TAFII110 (30). The C-terminal third
of these subunits is highly conserved (17, 30). The N terminus of
TAFII105 is significantly more diverged and was shown to be
involved in interaction with activation domains of activators (19).
Unlike most TAF subunits that are conserved from yeast to human, no
homolog has been found for the family of hTAFII105,
hTAFII130, and dTAFII110 proteins in yeast,
suggesting that these TAFs might be involved in transcription regulatory pathways that do not exist in yeast.
TAFII105 was originally identified as TFIID-associated
polypeptide that is highly abundant in purified TFIID complex isolated from mature B cell line (30). Because the expression pattern of a
transcription factor usually correlates with its function, it was
postulated that TAFII105 may be involved in B cell-specific transcription (30). TAFII105 appears to be present only in
a subset of TFIID complexes, and therefore is likely to function in the
context of a specific set of genes. Consistent with these assumptions,
our previous analysis of TAFII105 function revealed that it
acts as an activation domain-specific coactivator of p65/RelA, a
subunit of the NF- In the present study we investigated the role of TAFII105
in transcription regulation mediated by the octamer motif. The octamer motif plays a crucial role in directing the B cell-specific expression of immunoglobulin and other B cell-specific genes. This motif is found
in the promoters and enhancers of all immunoglobulin genes and is
essential for the B cell-specific expression of these genes (31). Two
octamer-binding factors are expressed in B cells, a ubiquitous protein
Oct1 and the B cell-specific factor Oct2. These proteins associate with
a B cell-specific cofactor OCA-B also known as OBF-1 and Bob1 (32-34).
OCA-B interacts with Oct1 and Oct2 via its N terminus and provides a
strong activation domain to this complex.
Our studies reveal that TAFII105 plays a transcription
coactivator role required for a high level of B cell-specific octamer activity. Dissection of the molecular mechanism involved in the effect
of TAFII105 on octamer transcription revealed that
TAFII105 interacts with octamer-binding complexes through
direct interaction with the cofactor OCA-B. This interaction is
required for TAFII105 enhancement of
octamer-dependent activity and is mediated by the C-terminal activation domain of OCA-B and the coactivation domain of
TAFII105. These results suggest that TAFII105
is an additional regulatory component of octamer-dependent
B cell-specific gene expression, acting as coactivator for
octamer-binding complexes.
In Vitro Transcription
For the in vitro transcription reactions we used
nuclear extract prepared from the B cell line Daudi. The reaction
mixture (18 µl) contained 3 µl of extract, 6 µl of transcription
buffer (20 mM Hepes, pH 7.9; 100 mM KCl; 2 mM MgCl2; 0.2 mM EDTA; 20% glycerol; and 1 mM dithiothreitol), 0.6 µl of 0.1 M MgCl2, 40 units of RNasin, and 200 ng of DNA
template. The reaction was incubated at 30 °C for 30 min. Then 2 µl of the nucleotide mixture was added (for IgH and 2xOct/IgH G-less
reporters: 5 mM ATP and UTP, 1 mM
3'-O-methyl-GTP, and 100 µM
[ Plasmids
Expression Vectors--
Full-length OCA-B was generated by
polymerase chain reaction (PCR) using a Daudi cell cDNA library and
the following oligonucleotides: 5'-CCGAATTCCATATGCTCTGGCAAAAACCCACAG -3'; 5'-
TCCCAGTTTCAGGGAACAGGA-3'. For in vitro transcription and
translation of OCA-B, the PCR fragment was digested by NdeI
and was cloned into NdeI-StuI sites of a pT
TAFII130 Reporter Constructs--
The Oct-TATA reporter plasmid was
constructed by inserting a double-stranded synthetic oligonucleotides
(see below) containing a single octamer motif as a
HindIII-Blunt fragment into the
HindIII-Ecl136II sites upstream to a minimal
The construct Oct TATA/SV40 was generated by subcloning an Oct TATA
HindIII-NarI fragment from pOct-TATA into
HindIII-NarI of pGL2-enhancer vector (Promega).
An Oct-less/SV40 construct was created by inserting a
SacI-NarI fragment from pLuc- OCA-B Mutants--
To obtain the OCA-B 1-230 mutant, pCGN-OCA-B
was first digested with XbaI, followed by a partial digest
with HincII, and the fragment was subcloned into
XbaI-SmaI of the pCGN vector. pT
Details on the generation of Gal4-OCA-B fusion proteins can be given by request.
In Vitro Binding Experiments
The N and C termini of TAFII105, and
TAFII130 N-terminal fragments were expressed as a GST
fusion protein in Escherichia coli. The recombinant proteins
were purified and immobilized on glutathione-Sepharose beads.
35S-labeled Oct1, Oct2, and various OCA-B-derived proteins
were synthesized in vitro using T7 RNA polymerase and rabbit
reticulocytes lysate (Promega TNT kit), and incubated with the
different GST-purified proteins in 0.1 M KCl HEMG buffer
(20 mM Hepes, pH 7.9; 100 mM KCl; 12.5 mM MgCl2; 0.2 mM EDTA; 0.1%
Nonidet P-40; 1 mM dithiothreitol; 0.2 mM
phenylmethylsulfonyl fluoride) for 2 h at 4 °C. The beads were
washed three times with the same buffer and twice with 0.2 M KCl HEMG buffer. The bound proteins were eluted by
boiling for 5 min in protein sample buffer followed by
SDS-polyacrylamide gel electrophoresis (PAGE) and autoradiography.
Nuclear extract from BJAB cells was prepared as described (30). 50 µl
of nuclear extract (15 mg/ml) in 0.1 M HEMG + 0.1% Nonidet
P-40 were incubated with GST105 Transfections and Cell Lines
293 cells (embryonic kidney fibroblasts) were maintained in F-12
Dulbecco's modified Eagle's medium supplemented with 10% fetal calf
serum. Transfections were performed using the standard CaPO4 method. For reporter assays, subconfluent cells were
transfected with the indicated plasmids in a 24-well multidish using a
total of 0.8 µg of plasmid, usually 100 ng of the reporter gene, 400 ng of pCGN-OCA-B, and 200 ng of pCGN-TAFII105. The amount
of CMV vector in each transfection was kept constant.
BJAB (human), S194 (mouse), mature B cells were maintained in RPMI
medium supplemented with 10% fetal calf serum. Transfections to S194
stably expressing TAFII105 were done according to the DEAE-dextran method, using 0.5-1 µg of reporter plasmid in a total of 8.5 µg of DNA, in 100-mm dishes. To analyze the effect of dominant negative TAFII105, a transfection assay was performed using
3 µg of reporter plasmid and 12 µg of TAFII105 TAFII105 Is Involved in Octamer-dependent
Transcription in B Cells--
As a first step in testing the possible
involvement of TAFII105 in octamer-dependent
transcription, we established a pool of S194 B cells constitutively
expressing hTAFII105. These and control cells were
transfected with two different octamer-dependent luciferase
reporter genes (Fig. 1B), one
contains four tandem octamer sites and the other has a single octamer
site upstream to a minimal core promoter element. As shown in Fig.
1B, octamer-dependent luciferase activity is
higher in TAFII105-expressing cells. The activities of
reporter plasmids containing mutated octamer motifs or lacking octamer
motif were almost undetectable and were unaffected by
TAFII105 expression (columns 5-8). Although the fold of
induction of octamer activity was not high, it was highly reproducible. Considering the results shown in the subsequent figures, it may be
explained by the low level of ectopic expression TAFII105
achieved in S194 cells relative to human 293 cells (Fig.
1A).
Next, we tested the potential of a C-terminal truncated form of
TAFII105 (TAFII105
To examine more directly the involvement of TAFII105 in
octamer-dependent transcription, we performed in
vitro transcription reactions using a reporter plasmid composed of
two octamer elements upstream of a minimal IgH core promoter (Fig.
1D, upper panel) and nuclear extract prepared
from the Daudi B cell line. As expected, the transcription level of the
octamer-containing reporter plasmid was significantly higher than the
core promoter alone (Fig. 1D, lower panel,
lanes 1 and 2) confirming that octamer-binding
proteins mediate octamer transcription in vitro. Antibodies
directed against TAFII105 N-terminal domain decreased 95%
of octamer-dependent transcription (compare lanes
2 and 3), whereas control antibodies have no effect on
octamer transcription (compare lanes 2 and 4). By
contrast, less then 8% reduction was observed on transcription mediated by the adenovirus major late core promoter, consistent with
our previous finding that approximately 10% of the TFIID contain
TAFII105 in Daudi nuclear extract (MLP, lanes
5-7). Taken together, these results suggest that
TAFII105 is involved in octamer-mediated transcription in B cells.
TAFII105 and OCA-B Cooperate to Activate Octamer
Transcription on Artificial and Native B Cell-specific
Promoters--
In B cells, gene activation through an octamer motif is
regulated by two octamer-specific binding proteins Oct1 and Oct2 and a
B cell-specific cofactor OCA-B (36). OCA-B is recruited to the octamer
site by direct interaction with the POU domains of Oct1 and Oct2 and
activates octamer-specific transcription by providing a transcription
activation function to Oct1 and Oct2 (32-34). To examine the role of
TAFII105 in octamer-mediated transcription, the effect of
OCA-B and TAFII105 expression on
octamer-dependent transcription activity was tested using
transient transfection experiments in the human kidney fibroblast cell
line 293. In these cells OCA-B is brought to the promoter by the
ubiquitously expressed Oct1 protein. Luciferase reporter plasmid
containing a minimal core promoter element and an upstream octamer site
were cotransfected together with OCA-B or TAFII105
expression plasmids and luciferase activity was determined. To observe
a coactivation effect by both proteins, we used limiting amounts of
each factor. As shown in Fig.
2A, expression of
TAFII105 and OCA-B resulted in a marked increase of octamer
activity relative to the expression of each of these proteins alone
(compare column 4 with columns 2 and
3). This stimulation is specific because coexpression of
TAFII130, a TFIID subunit related to TAFII105,
has no stimulatory effect on octamer activity (data not shown).
Moreover, TAFII105 fails to stimulate the reporter
plasmid-lacking octamer site in the presence or absence of OCA-B
(columns 5-8), ruling out the possibility that
TAFII105 affects core promoter function.
To examine the role of TAFII105 in transcription of
physiologically relevant genes, we used a luciferase reporter gene
driven by promoters of two B cell-specific genes, immunoglobulin kappa light chain (Ig OCA-B Interacts with TAFII105--
To determine the
mechanism involved in TAFII105 action on octamer
transcription, we tested whether octamer factors can interact with
TAFII105. For this purpose nuclear extract prepared from the B cell line BJAB was incubated with immobilized
TAFII105 (N terminus, amino acids 1-552), and the bound
proteins were analyzed by Western blot using antibodies specific to
Oct2 and OCA-B. As shown in Fig.
3A, both Oct2 and OCA-B were
retained on TAFII105-containing beads but not on GST beads.
The binding of Oct2 and OCA-B is specific because RelB, another B cell
transcription factor, failed to associate with GST-TAFII105
on the same experiment.
Because OCA-B is complexed in B cells with Oct1 and Oct2, we tested
which of these proteins binds directly to TAFII105. Each of
the proteins Oct1, Oct2, and OCA-B was in vitro translated in rabbit reticulocytes lysate and used for binding assay with Sepharose-bound N-terminal or C-terminal fragments of
TAFII105. As shown in Fig. 3B, among the
proteins tested, only OCA-B specifically and efficiently interacts with
the N-terminal domain of TAFII105. The binding of OCA-B to
the TAFII105 N terminus is specific because it does not
interact with protein fragments derived from the N terminus of
hTAFII130 (Fig. 3C), which is consistent with
the low level of homology between TAFII105 and
TAFII130 within this region. Considering the inhibition of
octamer activity in B cells by a C-terminal truncated form of
TAFII105 (Fig. 1C) and the direct association of
OCA-B with this domain, it is reasonable to assume that this mutant
exerts its inhibitory effect by competing with native
TAFII105 protein for OCA-B binding.
TAFII105-OCA-B Interaction Is Important for Octamer
Transcription--
To obtain further evidence that the effect of
TAFII105 on octamer-dependent transcription is
mediated by OCA-B, we have constructed a mutant of OCA-B lacking the
last 26 amino acids (OCA-B 1-230) and analyzed it for
TAFII105 binding capacity and transcription activity. As
shown in Fig. 4A, deletion of
the last 26 residues significantly reduced TAFII105
binding. This mutant is incapable of stimulating octamer transcription
in 293 cells (Fig. 4B). Consistent with TAFII105
reduced binding capacity, co-expression of TAFII105 with
the OCA-B 1-230 mutant fails to enhance its activity (Fig. 4B). These results suggest that the interaction between
TAFII105 and OCA-B is important for activation of
octamer-dependent transcription.
Previous studies have indicated that OCA-B contains two transcription
activation domains. One domain is mapped to position 65-122, and the
second domain resides within the extreme C-terminal region (37-39). To
determine which of the activation domains is involved in
TAFII105 coactivation function and to further confirm that
OCA-B directly mediates TAFII105 effect, different OCA-B domains were fused to the yeast Gal4 DNA binding domain (Fig. 5A). These Gal4 fusion
proteins were cotransfected with luciferase reporter gene driven by
Gal4 sites upstream to a minimal core promoter. Gal4 DNA binding domain
alone (Gal4-DBD) lacks transcription activity and is not induced by
TAFII105 (Fig. 5B, columns 3 and 4). OCA-B mutants 1-230 and 1-122 but not 1-100,
stimulate the reporter activity (columns 5, 7,
and 9) suggesting that residues within the region of
100-122 of OCA-B are crucial for the N-terminal activation function.
However, these C-terminal truncated proteins are not responsive to
TAFII105 expression (columns 6, 8,
and 10). An N-terminal truncation of OCA-B (amino acids
100-256) also contains a strong activation domain (column
11). The activity of this mutant is elevated by
TAFII105 expression (column 12), confirming that coactivation by TAFII105 is mediated by the C-terminal
activation domain. Interestingly, OCA-B mutant 1-230 is active in the
context of fusion with Gal4 DBD, whereas it is inactive in the context of the native protein, raising the possibility that the N-terminal activation domain of OCA-B 1-230 is hidden and becomes exposed in the
fusion form.
Detailed analysis of B cell-specific transcription regulation by
the octamer motif revealed the involvement of two octamer-binding factors, the ubiquitous Oct1 and the B cell-restricted Oct2. These factors are not sufficient to reconstitute a high level of octamer activity observed in B cells. This activity is fulfilled by OCA-B, a B
cell-specific cofactor (also termed OBF-1 and Bob1) that is specifically brought to octamer sites by the Oct1 and Oct2 proteins (32-34). In the present study we provide evidence that
octamer-dependent activity in B cells is more complex and
also involves the B cell-enriched TFIID subunit TAFII105 as
transcription coactivator for octamer-binding complexes.
Using in vitro transcription studies we show that
octamer-mediated transcription, reconstituted with B cell nuclear
extract, is TAFII105-dependent. Protein-protein
interaction assays and reporter gene analysis revealed that OCA-B but
not Oct1 or Oct2 directly binds TAFII105 and that this
interaction is essential for stimulation of octamer activity.
Furthermore, we show that cooperation between OCA-B and
TAFII105 is more efficient on native B cell-specific
promoters carrying the octamer motif. Consistent with a coactivator
model, this interaction is mediated by the main OCA-B activation domain
and the N-terminal coactivation domain of TAFII105. Given
the high concentration of OCA-B and TAFII105-TFIID in the
nucleus of B lymphocytes, these two proteins are likely to efficiently
associate and stimulate the transcription of specific octamer-containing target genes in B cells. Because OCA-B stimulates transcription in B cells only through proximal octamer sites (38), it
will be interesting to determine whether TAFII105 is also
involved in transcription activation of a distally located octamer
motif that requires Oct2 and another unidentified B cell-restricted cofactor (40).
Unlike core TFIID-associated factors, TAFII105 is found in
a relatively small portion of TFIID complexes, 5-10% in certain mature B cell lines and 0.5-1% in non-B cells (30). Therefore, TAFII105-containing TFIID is likely to be involved in
transcription regulation of small fraction of genes. Given that the
amount of TFIID in the cell is limiting, activators capable of
TAFII105 binding might have an advantage in competing for
limiting TFIID and can more efficiently recruit
TAFII105-TFIID to their gene target. This is particularly
important for genes that should be rapidly induced and highly
transcribed such as immunoglobulin genes following antigenic
stimulation, or as we have previously shown, tumor necrosis
factor- The last C-terminal 26 amino acid residues of OCA-B contain an
activation domain crucial for OCA-B function. Deletion of this region
abrogates the ability of OCA-B to stimulate
octamer-dependent transcription. This result is similar to
an earlier report in which mutation of acidic amino acid residues
within this region significantly impaired OCA-B activity in
vitro and in transfected HeLa cells (39). Consistent with the
notion that direct interaction between TAFII105 and OCA-B
is involved in octamer transcription in vivo,
TAFII105 failed to stimulate transcription activation by
the OCA-B protein lacking the C-terminal domain (OCA-B 1-230) and to
efficiently bind this mutant protein.
Besides the C-terminal activation domain, another activation domain
within OCA-B was identified and mapped to amino acid residues 65-122
(37, 38). Our studies revealed that the N-terminal activation domain is
not targeted by TAFII105. On the basis of the failure of
OCA-B 1-230 to stimulate transcription and the facts that larger
C-terminal deletions of OCA-B (37) as well as C-terminal truncated Gal4
fusion protein of OCA-B (1-230 and 1-122) are transcriptionally
active, it is possible that the region within amino acids 192-230
contains an activation inhibitory function.
Previous biochemical analysis of OCA-B activity revealed that the USA
component PC4 is required for transcription activation by OCA-B in a
partially purified transcription system (39). In addition, using a
PC4-depleted HeLa nuclear extract, these authors also revealed the
existence of an additional and redundant OCA-B coactivator activity. It
should be noted that cooperation of TAFII105 and OCA-B for
transcriptional activation in HeLa cells was not observed (data not
shown). These findings together with the present study indicate that
OCA-B can utilize alternative pathways for transcription activation in
different cell types. It is also possible that in vivo,
under some circumstances, different OCA-B coactivators might cooperate
during different steps of the transcription activation process.
Consistent with this notion is the finding that the coactivation
function of PC4 is dependent on TAFs (41, 42).
Certain in vitro transcription studies indicated that TAFs
are absolutely required for transcription activation (9, 10). However,
recent studies revealed a mechanism of transcription activation that is
TAF-independent (43, 44). The existence of transcription activation
pathways with redundant coactivator activities raises the interesting
possibility that in vivo, gene-specific regulation is
determined by the combinatorial action of different sets of
coactivators, therefore providing an additional level of control.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
B family of transcription factors (19). These
studies also indicated that the p65·TAFII105 complex is involved in cytokine-mediated gene expression and anti-apoptotic gene
activation (19).
![]()
MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
-32P]CTP; and for the major late promoter (MLP)
U-less reporter: 5 mM ATP and GTP and 100 µM
[
-32P]CTP), and the reaction was incubated for
additional 10 min at 30 °C. The reaction was stopped by adding 200 µl of stop mixture (2 M NH4AC; 10 mM EDTA; 10 mM Tris, pH 7.4; and 0.25 µg/ml
tRNA), phenol chloroform extracted, and ethanol precipitated and run on
a 6% sequencing gel. When antibodies were used in the assay, they were
pre-incubated with the transcription mixture in the absence of the DNA
template for 30 min, followed by the procedure described above.
Anti-TAFII105 antibodies used in the transcription are
polyclonal antibodies directed against amino acids 1-552 (30). The
anti-HBV core antibodies were kindly provided by Dr. Y Shaul.
stop vector. The sequence of the PCR fragment was determined and
found to be correct. A mammalian expression vector for OCA-B (pCGN-OCA-B) was generated in two steps. An
NdeI-Ecl136II fragment from pT
-OCA-B was first
subcloned into NdeI-HincII sites of pBSNLS-HA downstream to a nuclear localization signal and HA tag. Next, a
SmaI fragment from this plasmid was inserted into the
SmaI site of pCGN vector (35). TAFII105
expression plasmid was created by inserting an NcoI (filled
in) and a BglII fragment from pVLHA-TAFII105 into SmaI-BamHI sites of pCGN.
TAFII105 retroviral expression vector (pBabe-105) was
generated using a three-point ligation reaction. An
Ecl136II-NcoI fragment from pCGN-105
C
containing the thymidine kinase leader sequence and an
NcoI-SalI fragment from the
pT
-TAFII105 plasmid, encoding for TAFII105,
were ligated into SnaBI-SalI sites of a pBabe-neo
vector. pT
-TAFII105 was created by inserting an
NdeI fragment from pVLFlag-TAFII105, previously described (30) into the NdeI site of pT
stop.
TAFII105
N plasmid fused to glutathione
S-transferase (GST) was generated by PCR using:
5'-CGATGAGGATGACATCAATG-3' and T7 primers.
Bluescript-TAFII105 was used as a template with the
proofreading PWO enzyme (Roche Molecular Biochemicals). The PCR product
was ligated into StuI-EcoRI sites of the
pT
stop vector, followed by subcloning into
NcoI-EcoRI sites of vector pGEX.
C (a), fused to GST, was cloned by digesting the
TAFII130
C plasmid with
NcoI-HincII, at amino acids 484-757, and cloning
into NcoI-StuI of vector pGEX-2TKN. The fragment
GST-130
C (b), amino acids 100-468, was cloned using a
NcoI-StuI digest and inserted into the pGEX-2TKN
vector in the NcoI-StuI sites.
-actin core promoter (
40 to +80) of pLuc-
-actin vector.
Octamer oligonucleotides were as follows: 5'-AGCTTTCAGGGTATGCAAATTATTAAGTCTCG-3' and
5'-CGAGACTTAATAATTTGCATACCCTGAA-3'.
-actin plasmid into the
SacI-NarI sites of pGL2-enhancer plasmid. The 4xOct wild type and 4xOct mutant plasmids were a generous gift from Dr.
T. Wirth. The J chain reporter plasmid was kindly provided by the late
M. Koshland, and the Ig
luciferase was described previously (30).
The reporter plasmid 2xOct/IgH, used for in vitro
transcription, was constructed by using two oligonucleotides; 5'-AATAATTTGCATACCCTAATTTGCATACG-3' and
5'-AATTCGTATGCAAATTAGGGTATGCAAATTATT-3'. The two oligonucleotides were
annealed and ligated into IgH (G-less cassette) in
EcoRI-Ecl136II sites.
-OCA-B 1-230
was constructed by inserting an NdeI-HincII
(partial digest) fragment into NdeI-StuI sites of
pT
stop vector.
C or with GST beads as described
above. After the washes, bound proteins were eluted with 1 M NaCl HEMG, loaded onto an SDS-PAGE, and analyzed by
Western blot, using anti-OCA-B, anti-Oct2, and anti-RelB antibodies
(Santa Cruz Biotechnologies).
C
plasmid. The amount of CMV vector in each transfection was kept
constant. A pool of S194 cells expressing TAFII105 was
generated in two steps. First, TAFII105 retroviral
particles were produced in 293 cells. Briefly, 293 cells were seeded at
a density of 1 × 106 cells in 50-mm plates 24 h
before transfection. Shortly before transfection, medium was replaced
with fresh Dulbecco's modified Eagle's medium/10% fetal calf serum
containing 25 µM chloroquine. 10 µg of DNA containing
pBabe-TAFII105 and
helper vector at a 1:1 ratio were
transfected into the cells using the calcium phosphate-DNA
coprecipitation method. After 8 h, the medium was replaced with a
fresh one. Supernatant containing viral particles was harvested 48 h after transfection and filtered through a 0.45-µm filter. To infect
S194 cells with the virus, 2 ml of the viral supernatant and polybrene
(final concentration, 5 µg/ml) were used to infect 0.5 × 106 cells. After incubation at 37 °C for 2.5 h,
an additional 8 ml of RPMI/10% fetal calf serum was added to each
plate. Cells were incubated at 37 °C for an additional 1-1.5
days before addition of G418 (1 mg/ml; the active component is
~0.5 mg/ml). Medium was changed every 3-4 days. Pools of
G418-resistant cells were analyzed by Western blotting using the
anti-TAFII105 polyclonal antibodies.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

View larger version (15K):
[in a new window]
Fig. 1.
Ectopic expression of hTAFII105
in S194 cells elevates octamer-dependent
transcription. A, stable S194 cells (mouse B cells)
expressing human TAFII105 were generated (as described
under "Materials and Methods") and analyzed by Western blot using
anti- hTAFII105 antibodies. 293 cells overexpressing
TAFII105 were used as positive control. B,
reporter plasmids (shown schematically at top) driven by
four tandems repeats of the wild type octamer motif (4xOct
w.t), a mutated version of the four octamers (4xOct
mutant), a single octamer motif upstream to a minimal
-actin
promoter (Oct TATA/SV40) and
-actin promoter alone
(TATA/SV40) were transfected into parental S194 cells or
into a pool of TAFII105 expressing S194 cells as indicated.
Luciferase activity was measured, and the activity of the wild-type
reporters was normalized to 1. Standard error bars were calculated from
at least three independent experiments. C, dominant negative
TAFII105 inhibits octamer-dependent
transcription in B cells. BJAB and S194 B cell lines were transfected
with oct-TATA/SV40 reporter plasmid together with expression plasmid of
TAFII105
C. Luciferase activity of three independent
experiments was measured. D, TAFII105 mediates B
cell octamer transcription in vitro. Upper panel,
schematic representation of reporter plasmids used for in
vitro transcription assay. IgH TATA is a minimal IgH core promoter
element [(
47)-(+1)], 2xOct/IgH TATA contains two tandem octamer
motifs upstream to the IgH promoter, and MLP TATA contains the
adenovirus major late core promoter that is used as specificity
control. Lower panel, the activity of the promoters was
examined in vitro using Daudi B cell crude nuclear extract
in the absence or presence of TAFII105 and
HBV-core-specific antibodies as indicated at the top of the
lanes. The reaction of lane 1 was carried out
with IgH TATA reporter, whereas in lanes 2-4, 2xOct/IgH
TATA was used. The MLP TATA reporter was used in lanes
5-7.
C) to inhibit octamer
transcription. This mutant is deleted of the C-terminal TFIID-binding
domain and was previously shown to act as a dominant negative mutant of
TAFII105 function (19). BJAB and S194 B cell lines were
transfected with octamer-dependent reporter plasmid
together with expression plasmid for TAFII105
C. As shown
in Fig. 1C, TAFII105
C inhibited octamer transcription in both cell lines.

View larger version (10K):
[in a new window]
Fig. 2.
Stimulation of octamer-dependent
activity by TAFII105 and OCA-B. A, reporter
plasmids containing a single octamer site (columns 1-4) or
TATA box only (columns 5-8) were transfected into human 293 cells together with either empty expression vector or ex pression plasmids for OCA-B or TAFII105 as indicated
at the bottom of each lane. Transcriptional
activation of B cell-specific promoters by OCA-B and
TAFII105 was analyzed by transfection assays using
luciferase reporter plasmids driven by the promoters of Ig
light
chain (B) and J chain (C). Each promoter contains
an octamer sequence as shown. These promoters were introduced into 293 cells along with limiting amounts of OCA-B expression plasmid
(columns 2 and 4) and TAFII105
(columns 3 and 4), and luciferase activity was
measured. The activity of the reporter alone was normalized to 1. The
amount of CMV-derived vector in each transfection was kept constant.
Expression of all effector plasmids was confirmed by Western blot (data
not shown). The results of these transfection experiments are the
average of three independent experiments with similar results.
) and J chain. The proximal promoter region of both
genes contains an octamer site. As expected, the promoter activity of
these genes in non-B cells is very low (Fig. 2, B and
C). Cotransfection of either OCA-B or TAFII105
with these reporter plasmids, has minor effect on Ig
and J chain
promoter activities (Fig. 2, B and C,
columns 2 and 3). However, transfection of OCA-B
and TAFII105 with the B cell-specific reporter genes resulted in strong stimulation of reporter gene activity, suggesting that OCA-B and TAFII105 collaborate to stimulate the
activity of these promoters. The potentiation of OCA-B activity by
TAFII105 in the context of the native promoters is greater
then that observed with the artificial promoter (Fig. 2A),
raising the possibility that the organization of the native promoters
is more suitable for activation by OCA-B and TAFII105.
Taken together, these results suggest that TAFII105
coactivator function on the octamer element is mediated by OCA-B.

View larger version (33K):
[in a new window]
Fig. 3.
Specific interaction of hTAFII105
with OCA-B. A, purified TAFII105 protein
(GST105
C, amino acids 1-552) fused to GST and bound to
glutathione-Sepharose beads, or control GST-containing beads were used
for binding reaction with nuclear extract prepared from the human B
cell line BJAB. The bound proteins were eluted by high salt and
subjected to SDS-PAGE followed by Western blot analysis using
anti-OCA-B, anti-Oct2, or anti-RelB antibodies. Input lanes represent
10% of the total nuclear extract used for the binding. B,
TAFII105 interacts directly with OCA-B through its
N-terminal domain. Oct1, Oct2, and OCA-B proteins were
translated in vitro and labeled with
[35S]methionine using rabbit reticulocyte lysate. These
proteins were used for binding assay using GST105
C described in
A or GST105
N protein (amino acids 551 to end). The bound
proteins were eluted, resolved by SDS-PAGE, and autoradiographed. Input
lanes represent 10% of the total protein used. C, OCA-B
interacts specifically with TAFII105 but not with
TAFII130. Translated OCA-B protein was analyzed for the
ability to bind the N-terminal domain of TAFII130 protein
homologous to the N-terminal domain of TAFII105. To achieve
reasonable levels of expression, TAFII130 protein was
dissected into two fragments: (a) and (b). Fragment (b) was found to be
competent for protein-protein interaction, as it efficiently binds SP1
(data not shown).

View larger version (23K):
[in a new window]
Fig. 4.
Deletion of the last 26 amino acid residues
of OCA-B severely reduced TAFII105 binding and its
transcription activity. A, binding reaction between
immobilized TAFII105 (GST105
C) or GST proteins and
in vitro translated and labeled wild type OCA-B 1-256
(lanes 1-3) or mutant OCA-B 1-230 (lanes 4-6).
The bound proteins were washed, eluted, and subjected to SDS-PAGE
followed by autoradiography. Input lanes represent 10% of the total
protein used for the binding. The binding of wild type OCA-B to
TAFII105 relative to the input represent 100% of binding.
B, effect of the truncated form of OCA-B (1-230) on octamer
transcription. 293 cells were cotransfected with the single
octamer-reporter construct and expression plasmids for OCA-B 1-230
(columns 2 and 4) and TAFII105
(columns 3 and 4). Expression of mutated OCA-B
was verified by Western blot using anti-HA antibodies (data not shown).
Luciferase activity of the reporter cotransfected with empty expression
vector (column 1) was normalized to 1.

View larger version (17K):
[in a new window]
Fig. 5.
The C-terminal activation domain of OCA-B
mediates TAFII105 effect and directs TAFII105
binding. A, schematic presentation of GAL4 fusion
protein series with different OCA-B domains. B,
transcription activity of the Gal4 chimeric proteins. 293 cells were
transfected with a luciferase reporter plasmid containing five tandem
Gal4 binding sites together with the indicated Gal4 fusion proteins in
the presence (even-numbered columns) or absence
(odd-numbered columns) of TAFII105 expression
plasmid. The amount of CMV-derived vector in each transfection assay
was kept constant. The expression of the different OCA-B mutants and
TAFII105 was verified by Western blot (data not
shown).
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
-induced anti-apoptotic genes (19).
| |
FOOTNOTES |
|---|
* This work was supported by grants from the Minerva Foundation, Germany, by The Israel Cancer Research Fund, and by the Leo and Julia Forcheimer Center for Molecular Genetics.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Incumbent of the Martha S. Sagon Career Development Chair. To whom
correspondence should be addressed. Tel.: 972-8-934-2117; Fax:
972-8-934-4118; E-mail: bcrivka@wiccmail.weizmann.ac.il.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: TAF, TATA-binding protein associated factor; MLP, major late promoter; PCR, polymerase chain reaction; GST, glutathione S-transferase; HA, hemagglutinin.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Henderson, A., and Calame, K. (1998) Annu. Rev. Immunol. 16, 163-200[CrossRef][Medline] [Order article via Infotrieve] |
| 2. | Pugh, B. F., and Tjian, R. (1990) Cell 61, 1187-1197[CrossRef][Medline] [Order article via Infotrieve] |
| 3. |
Horikoshi, M.,
Wang, C. K.,
Fujii, H.,
Cromlish, J. A.,
Weil, P. A.,
and Roeder, R. G.
(1989)
Proc. Natl. Acad. Sci. U. S. A.
86,
4843-4847 |
| 4. | Dynlacht, B. D., Hoey, T., and Tjian, R. (1991) Cell 66, 563-576[CrossRef][Medline] [Order article via Infotrieve] |
| 5. |
Tanese, N.,
Pugh, B. F.,
and Tjian, R.
(1991)
Genes Dev.
5,
2212-2224 |
| 6. |
Zhou, Q.,
Lieberman, P. M.,
Boyer, T. G.,
and Berk, A. J.
(1992)
Genes Dev.
6,
1964-1974 |
| 7. |
Poon, D.,
and Weil, P. A.
(1993)
J. Biol. Chem.
268,
15325-15328 |
| 8. | Reese, J. C., Apone, L., Walker, S. S., Griffin, L. A., and Green, M. R. (1994) Nature 371, 523-527[CrossRef][Medline] [Order article via Infotrieve] |
| 9. | Verrijzer, C. P., and Tjian, R. (1996) Trends Biochem. Sci. 21, 338-342[CrossRef][Medline] [Order article via Infotrieve] |
| 10. |
Hoffmann, A.,
Oelgeschlager, T.,
and Roeder, R. G.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
8928-8935 |
| 11. | Chen, J. L., Attardi, L., Verrijzer, C. P., Yokomori, K., and Tjian, R. (1994) Cell 79, 93-105[CrossRef][Medline] [Order article via Infotrieve] |
| 12. |
Thut, C. J.,
Chen, J. L.,
Klemm, R.,
and Tjian, R.
(1995)
Science
267,
100-104 |
| 13. |
Sauer, F.,
Hansen, S. K.,
and Tjian, R.
(1995)
Science
270,
1783-1788 |
| 14. | Verrijzer, C. P., Chen, J. L., Yokomori, K., and Tjian, R. (1995) Cell 81, 1115-1125[CrossRef][Medline] [Order article via Infotrieve] |
| 15. |
Burke, T. W.,
and Kadonada, J. T.
(1996)
Genes Dev.
10,
711-724 |
| 16. | May, M., Mengus, G., Lavigne, A. C., Chambon, P., and Davidson, I. (1996) EMBO J. 15, 3093-3104[Medline] [Order article via Infotrieve] |
| 17. |
Mengus, G.,
May, M.,
Carry, L.,
Chambon, P.,
and Davidson, I.
(1997)
Genes Dev.
11,
1381-1395 |
| 18. |
Wang, E. H.,
Zou, S.,
and Tjian, R.
(1997)
Genes Dev.
11,
2658-2669 |
| 19. | Yamit-Hezi, A., and Dikstein, R. (1998) EMBO J. 17, 5161-5169[CrossRef][Medline] [Order article via Infotrieve] |
| 20. |
Zhou, J.,
Zwicker, J.,
Szymanski, P.,
Levine, M.,
and Tjian, R.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
13483-13488 |
| 21. | Apone, L. M., Virbasius, C. A., Holstege, F. C., Wang, J., Young, R. A., and Green, M. R. (1998) Mol. Cell 2, 653-661[CrossRef][Medline] [Order article via Infotrieve] |
| 22. | Michel, B., Komarnitsky, P., and Buratowski, S. (1998) Mol. Cell 2, 663-673[CrossRef][Medline] [Order article via Infotrieve] |
| 23. | Moqtaderi, Z., Keaveney, M., and Struhl, K. (1998) Mol. Cell 2, 675-682[CrossRef][Medline] [Order article via Infotrieve] |
| 24. | Natarajan, K., Jackson, B. M., Rhee, E., and Hinnebusch, A. G. (1998) Mol. Cell 2, 683-692[CrossRef][Medline] [Order article via Infotrieve] |
| 25. |
Sanders, S. L.,
Klebanow, E. R.,
and Weil, P. A.
(1999)
J. Biol. Chem.
274,
18847-18850 |
| 26. |
Komarnitsky, P. B.,
Michel, B.,
and Buratowski, S.
(1999)
Genes Dev.
13,
2484-2489 |
| 27. |
Apone, L. M.,
Virbasius, C. M. A.,
Reese, J. C.,
and Green, M. R.
(1996)
Genes Dev.
10,
2368-2380 |
| 28. | Moqtaderi, Z., Bai, Y., Poon, D., Weil, P. A., and Struhl, K. (1996) Nature 383, 188-191[CrossRef][Medline] [Order article via Infotrieve] |
| 29. | Walker, S. S., Reese, J. C., Apone, L. M., and Green, M. R. (1996) Nature 383, 185-188[CrossRef][Medline] [Order article via Infotrieve] |
| 30. | Dikstein, R., Zhou, S., and Tjian, T. (1996) Cell 87, 137-146[CrossRef][Medline] [Order article via Infotrieve] |
| 31. | Staudt, L. M., and Lenardo, M. J. (1991) Annu. Rev. Immunol. 9, 373-398[CrossRef][Medline] [Order article via Infotrieve] |
| 32. | Gstaiger, M., Knoepfel, L., Georgiev, O., Schaffner, W., and Hovens, C. M. (1995) Nature 373, 360-362[CrossRef][Medline] [Order article via Infotrieve] |
| 33. | Luo, Y., and Roeder, R. G. (1995) Mol. Cell. Biol. 15, 4115-4124[Abstract] |
| 34. | Strubin, M., Newell, J. M., and Mattias, P. (1995) Cell 80, 497-506[CrossRef][Medline] [Order article via Infotrieve] |
| 35. | Tanaka, M., and Herr, W. (1990) Cell 60, 375-386[CrossRef][Medline] [Order article via Infotrieve] |
| 36. | Matthias, P. (1998) Semin. Immunol. 10, 155-163[CrossRef][Medline] [Order article via Infotrieve] |
| 37. | Gstaiger, M., Georgiev, O., van Leeuwen, H., van der Vlier, P., and Schaffner, W. (1996) EMBO J. 15, 2781-2790[Medline] [Order article via Infotrieve] |
| 38. |
Pfisterer, P.,
Zwilling, S.,
Hess, J.,
and Wirth, T.
(1995)
J. Biol. Chem.
270,
29870-29880 |
| 39. |
Luo, Y.,
Ge, H.,
Stevens, S.,
Xiao, H.,
and Roeder, R. G.
(1998)
Mol. Cell. Biol.
18,
3803-3810 |
| 40. | Wirth, T., Pfisterer, P., Annweiler, A., Zwilling, S., and Konig, H. (1995) Immunobiology 193, 161-170[Medline] [Order article via Infotrieve] |
| 41. |
Malik, S.,
Guermah, M.,
and Roeder, R. G.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
2192-2197 |
| 42. |
Wu, S. Y.,
and Chiang, C. M.
(1998)
J. Biol. Chem.
273,
12492-12498 |
| 43. | Koleske, A. J., and Young, R. A. (1994) Nature 368, 466-469[CrossRef][Medline] [Order article via Infotrieve] |
| 44. | Oelgeschlager, T., Tao, Y., Kang, Y. K., and Roeder, R. G. (1998) Mol. Cell 1, 925-931[CrossRef][Medline] [Order article via Infotrieve] |
This article has been cited by other articles:
![]() |
H. Shao, M. Revach, S. Moshonov, Y. Tzuman, K. Gazit, S. Albeck, T. Unger, and R. Dikstein Core Promoter Binding by Histone-Like TAF Complexes Mol. Cell. Biol., January 1, 2005; 25(1): 206 - 219. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Ainbinder, L. Amir-Zilberstein, Y. Yamaguchi, H. Handa, and R. Dikstein Elongation Inhibition by DRB Sensitivity-Inducing Factor Is Regulated by the A20 Promoter via a Novel Negative Element and NF-{kappa}B Mol. Cell. Biol., March 15, 2004; 24(6): 2444 - 2454. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Hochheimer and R. Tjian Diversified transcription initiation complexes expand promoter selectivity and tissue-specific gene expression Genes & Dev., June 1, 2003; 17(11): 1309 - 1320. [Full Text] [PDF] |
||||
![]() |
R. N. Freiman, S. R. Albright, L. E. Chu, S. Zheng, H.-E. Liang, W. C. Sha, and R. Tjian Redundant Role of Tissue-Selective TAFII105 in B Lymphocytes Mol. Cell. Biol., September 15, 2002; 22(18): 6564 - 6572. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Silkov, O. Wolstein, I. Shachar, and R. Dikstein Enhanced Apoptosis of B and T Lymphocytes in TAFII105 Dominant-negative Transgenic Mice Is Linked to Nuclear Factor-kappa B J. Biol. Chem., May 10, 2002; 277(20): 17821 - 17829. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. J. Kolell and D. L. Crawford Evolution of Sp Transcription Factors Mol. Biol. Evol., March 1, 2002; 19(3): 216 - 222. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Kirchner, S. L. Sanders, E. Klebanow, and P. A. Weil Molecular Genetic Dissection of TAF25, an Essential Yeast Gene Encoding a Subunit Shared by TFIID and SAGA Multiprotein Transcription Factors Mol. Cell. Biol., October 1, 2001; 21(19): 6668 - 6680. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. N. Freiman, S. R. Albright, S. Zheng, W. C. Sha, R. E. Hammer, and R. Tjian Requirement of Tissue-Selective TBP-Associated Factor TAFII105 in Ovarian Development Science, September 14, 2001; 293(5537): 2084 - 2087. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. G. Bert, J. Burrows, A. Hawwari, M. A. Vadas, and P. N. Cockerill Reconstitution of T Cell-Specific Transcription Directed by Composite NFAT/Oct Elements J. Immunol., November 15, 2000; 165(10): 5646 - 5655. [Abstract] [Full Text] [PDF] |
||||
![]() |
|